Splenic marginal zone lymphoma: 2026 so far

Single-patient reports described both improvement and safety concerns.

In the months covered, treatment evidence in SMZL came mainly from single-patient reports, not head-to-head comparative studies. Reported responses included rituximab monotherapy (rituximab used alone) followed by marked clinical improvement and spleen-size reduction in one person. Another report described R-CVP chemotherapy (rituximab, cyclophosphamide, vincristine, prednisone) after splenectomy, followed by complete metabolic remission on PET/CT (a scan that looks for metabolically active cancer) in a person ultimately diagnosed with DLBCL (diffuse large B-cell lymphoma, a faster-growing lymphoma) rather than SMZL. Rare complications around rituximab-based care were also described in single cases. These included acquired hemophilia A (an autoimmune bleeding disorder) that improved after rituximab, and hepatitis B reactivation (the virus becoming active again) after rituximab-based chemotherapy despite baseline hepatitis B surface antibody positivity. A mild rituximab-related lung inflammation and an infection-related complication (neutropenic diverticulitis) were also reported. Taken together, the published experiences so far in 2026 show highly individualized outcomes, with both benefit and risk, and the evidence is mostly limited to case-level reports.

Research covered in: January 2026, February 2026, May 2026, July 2026

Some reports focused on uncommon symptoms and the supportive care they required.

Several reports from January 2026 to July 2026 described uncommon, high-burden presentations that strongly shaped day-to-day management. One example was chylous ascites (milky fluid buildup in the abdomen) that required repeated drainage and nutrition support in one case. Other single-patient reports linked SMZL care to unusual immune/bleeding or infection-related issues, including acquired hemophilia A presenting with bruising and hematuria (blood in the urine), and hepatitis B reactivation with marked liver enzyme elevation after rituximab-based chemotherapy. These reports also emphasized that other health conditions can drive symptoms or outcomes. One autopsy case attributed rapid decline to transthyretin amyloidosis (protein buildup disease) rather than lymphoma alone. In the published case literature so far in 2026, managing symptoms and complications was often central, but these reports cannot show how common these problems are or what the typical risk is.

Research covered in: January 2026, February 2026, June 2026, July 2026

Cohort and registry studies added signals about risk and follow-up needs.

Population-level studies in the months covered added information about monitoring and prognosis, rather than testing specific SMZL treatments. A multicenter cohort looked at an early marginal zone-type clonal B-cell finding (a small abnormal B-cell population) and reported that most people had a slow course. Only about 5% later developed SMZL. Within that cohort, more extensive bone marrow involvement and higher LDH (a blood test that can rise with cell turnover) were linked to a higher chance of needing treatment over time. Separately, a U.S. registry analysis linked overall survival to age and stage IV disease. It also reported survival differences across sex, Hispanic ethnicity, and marital status categories. The registry analysis also found worse survival among those recorded as receiving systemic anti-cancer therapy. The authors cautioned this should be read as selection patterns rather than treatment harm, because registry data lack key clinical details. In practical terms, these findings help explain why follow-up plans and outcome patterns can differ between people, while still leaving major uncertainty about treatment effects in real-world datasets.

Research covered in: May 2026, July 2026

Reports showed that imaging and symptoms alone often could not sort out the cause.

From January 2026 to July 2026, multiple case reports showed that an enlarged spleen or a splenic mass could be SMZL, aggressive lymphoma (DLBCL), both at once, or a closely related splenic lymphoma. In these reports, tissue-based evaluation (testing a sample from the spleen, lymph node, or bone marrow) often clarified what was present. Examples included splenectomy (surgical removal of the spleen) clarifying whether isolated splenomegaly (enlarged spleen) was SMZL versus DLBCL, a "wandering spleen" where SMZL was diagnosed after splenectomy with flow cytometry (a lab method that sorts cells by markers), and a focal splenic lesion that looked vascular on imaging but proved to be SMZL on pathology (microscope-based tissue diagnosis). Reports also highlighted diagnostic gaps where fluid testing could be non-diagnostic, such as abdominal fluid testing not showing a clear lymphoma B-cell population despite SMZL supported by marrow/imaging. In these published cases, the workup often depended on obtaining and correctly interpreting tissue, especially when the presentation was unusual or when the best treatment would differ by subtype.

Research covered in: January 2026, February 2026, May 2026, June 2026

Exploratory studies proposed measurable subgroups linked to outcome signals.

In the months covered, one large multiomic study (a study combining multiple types of biological data) proposed that SMZL may separate into two epigenetic (DNA methylation) groups with different time to first treatment and overall survival. This suggested measurable biological differences within SMZL. The authors noted the classifier needs independent confirmation and lacked an external validation group. A separate small pilot study involving SMZL and related slow-growing B-cell cancers suggested that certain blood-smear nuclear abnormalities (changes seen on a microscope slide of blood cells), summarized as a Cytological Instability Score, tracked with genomic/chromosomal complexity. This raised the possibility that routine microscopy features could act as a low-tech marker of instability if validated. As described so far in 2026, these risk-stratification approaches are research tools and were explicitly presented as exploratory, not as routine clinical tests.

Research covered in: May 2026, June 2026